PT-141
Also known as: Bremelanotide, Vyleesi, Melanocyte-Stimulating Hormone
The first FDA-approved peptide for sexual dysfunction — centrally acting with proven clinical results.
Molecular structure image coming soon
FDA-approved (Vyleesi) for women with HSDD. Requires prescription. May cause nausea, flushing, and transient blood pressure increases.
Overview
PT-141 (Bremelanotide) is a synthetic melanocortin peptide and the first FDA-approved treatment for hypoactive sexual desire disorder (HSDD) in premenopausal women (brand name Vyleesi). Unlike PDE5 inhibitors (sildenafil/tadalafil) which work through vascular mechanisms, PT-141 acts centrally through melanocortin receptors in the brain to enhance sexual desire and arousal in both women and men.
Mechanism of Action
PT-141 is an agonist of melanocortin receptors (MC3R and MC4R) in the hypothalamus and limbic system. This central mechanism directly increases sexual desire and arousal pathways, rather than working through vascular or hormonal changes.
Use Cases
- ✓Hypoactive sexual desire disorder (FDA-approved for women)
- ✓Female sexual arousal disorder
- ✓Male erectile dysfunction and libido (off-label)
- ✓Sexual dysfunction in both sexes
Research Summary
FDA approval was based on RECONNECT trials demonstrating significantly increased satisfying sexual events and reduced distress in women with HSDD. Off-label male studies show improved erectile function and libido, particularly effective when PDE5 inhibitors have failed.
Typical Dosing
FDA-approved: 1.75 mg subcutaneous injection 45 minutes before anticipated sexual activity (max 1x per 24 hours, 8x per month). Off-label male dose: 1–2 mg.
Administration
Prescription Only
FDA-approved (Vyleesi) for women with HSDD. Requires prescription. May cause nausea, flushing, and transient blood pressure increases.
